228 related articles for article (PubMed ID: 25609303)
1. Modeling of the Ebola virus delta peptide reveals a potential lytic sequence motif.
Gallaher WR; Garry RF
Viruses; 2015 Jan; 7(1):285-305. PubMed ID: 25609303
[TBL] [Abstract][Full Text] [Related]
2. Amino acid mutations in Ebola virus glycoprotein of the 2014 epidemic.
Giovanetti M; Grifoni A; Lo Presti A; Cella E; Montesano C; Zehender G; Colizzi V; Amicosante M; Ciccozzi M
J Med Virol; 2015 Jun; 87(6):893-8. PubMed ID: 25783989
[TBL] [Abstract][Full Text] [Related]
3. RNA Editing of the GP Gene of Ebola Virus is an Important Pathogenicity Factor.
Volchkova VA; Dolnik O; Martinez MJ; Reynard O; Volchkov VE
J Infect Dis; 2015 Oct; 212 Suppl 2():S226-33. PubMed ID: 26138826
[TBL] [Abstract][Full Text] [Related]
4. Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda.
Sanchez A; Rollin PE
Virus Res; 2005 Oct; 113(1):16-25. PubMed ID: 16139097
[TBL] [Abstract][Full Text] [Related]
5. Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus.
Volchkova VA; Klenk HD; Volchkov VE
Virology; 1999 Dec; 265(1):164-71. PubMed ID: 10603327
[TBL] [Abstract][Full Text] [Related]
6. Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus.
Falzarano D; Krokhin O; Wahl-Jensen V; Seebach J; Wolf K; Schnittler HJ; Feldmann H
Chembiochem; 2006 Oct; 7(10):1605-11. PubMed ID: 16977667
[TBL] [Abstract][Full Text] [Related]
7. Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013-2016 Epidemic.
Diehl WE; Lin AE; Grubaugh ND; Carvalho LM; Kim K; Kyawe PP; McCauley SM; Donnard E; Kucukural A; McDonel P; Schaffner SF; Garber M; Rambaut A; Andersen KG; Sabeti PC; Luban J
Cell; 2016 Nov; 167(4):1088-1098.e6. PubMed ID: 27814506
[TBL] [Abstract][Full Text] [Related]
8. Ebola virus envelope glycoprotein derived peptide in human Furin-bound state: computational studies.
Omotuyi IO
J Biomol Struct Dyn; 2015; 33(3):461-70. PubMed ID: 25347780
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of ebola virus GP1 in viral entry.
Manicassamy B; Wang J; Jiang H; Rong L
J Virol; 2005 Apr; 79(8):4793-805. PubMed ID: 15795265
[TBL] [Abstract][Full Text] [Related]
10. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.
Volchkov VE; Volchkova VA; Muhlberger E; Kolesnikova LV; Weik M; Dolnik O; Klenk HD
Science; 2001 Mar; 291(5510):1965-9. PubMed ID: 11239157
[TBL] [Abstract][Full Text] [Related]
11. Functional mutations in spike glycoprotein of Zaire ebolavirus associated with an increase in infection efficiency.
Ueda MT; Kurosaki Y; Izumi T; Nakano Y; Oloniniyi OK; Yasuda J; Koyanagi Y; Sato K; Nakagawa S
Genes Cells; 2017 Feb; 22(2):148-159. PubMed ID: 28084671
[TBL] [Abstract][Full Text] [Related]
12. Soluble Glycoprotein Is Not Required for Ebola Virus Virulence in Guinea Pigs.
Hoenen T; Marzi A; Scott DP; Feldmann F; Callison J; Safronetz D; Ebihara H; Feldmann H
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S242-6. PubMed ID: 25957965
[TBL] [Abstract][Full Text] [Related]
13. A new Ebola virus nonstructural glycoprotein expressed through RNA editing.
Mehedi M; Falzarano D; Seebach J; Hu X; Carpenter MS; Schnittler HJ; Feldmann H
J Virol; 2011 Jun; 85(11):5406-14. PubMed ID: 21411529
[TBL] [Abstract][Full Text] [Related]
14. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies.
Ito H; Watanabe S; Takada A; Kawaoka Y
J Virol; 2001 Feb; 75(3):1576-80. PubMed ID: 11152533
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.
Ito H; Watanabe S; Sanchez A; Whitt MA; Kawaoka Y
J Virol; 1999 Oct; 73(10):8907-12. PubMed ID: 10482652
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
17. Screening of commercial cyclic peptide conjugated to HIV-1 Tat peptide as inhibitor of N-terminal heptad repeat glycoprotein-2 ectodomain Ebola virus through in silico analysis.
Tambunan USF; Alkaff AH; Nasution MAF; Parikesit AA; Kerami D
J Mol Graph Model; 2017 Jun; 74():366-378. PubMed ID: 28482272
[TBL] [Abstract][Full Text] [Related]
18. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs.
Volchkova VA; Dolnik O; Martinez MJ; Reynard O; Volchkov VE
J Infect Dis; 2011 Nov; 204 Suppl 3():S941-6. PubMed ID: 21987773
[TBL] [Abstract][Full Text] [Related]
19. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses.
Volchkov VE; Blinov VM; Netesov SV
FEBS Lett; 1992 Jul; 305(3):181-4. PubMed ID: 1299611
[TBL] [Abstract][Full Text] [Related]
20. Identifying the pattern of molecular evolution for Zaire ebolavirus in the 2014 outbreak in West Africa.
Liu SQ; Deng CL; Yuan ZM; Rayner S; Zhang B
Infect Genet Evol; 2015 Jun; 32():51-9. PubMed ID: 25745889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
